Cargando…

Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper

The short-term mortality and rehospitalization rates after admission for acute heart failure (AHF) remain high, despite the high level of adherence to contemporary practice guidelines. Observational data from non-randomized studies in AHF strongly support the in-hospital administration of oral evide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ntalianis, Argyrios, Chrysohoou, Christina, Giannakoulas, George, Giamouzis, Grigorios, Karavidas, Apostolos, Naka, Aikaterini, Papadopoulos, Constantinos H., Patsilinakos, Sotirios, Parissis, John, Tziakas, Dimitrios, Kanakakis, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087533/ https://www.ncbi.nlm.nih.gov/pubmed/33931815 http://dx.doi.org/10.1007/s10741-021-10115-8

Ejemplares similares

Rationale and Design of Heart Failure Prevalence and Evolution of Heart Failure in Diabetes Mellitus Type II Patients at High Risk (HF-LanDMark Study)
por: Parissis, John, et al.
Publicado: (2023)

Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece
por: Athanasakis, Kostas, et al.
Publicado: (2016)

The effect of SGLT-2i administration on red blood cell distribution width in patients with heart failure and type 2 diabetes mellitus: A randomized study
por: Katsiadas, Nikolaos, et al.
Publicado: (2022)

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus
por: Gan, Liangying, et al.
Publicado: (2022)

Neprilysin in HFrEF: Differential Regulation of Tissue Versus Circulating Neprilysin
por: Chen, Horng H., et al.
Publicado: (2020)

Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2014)

Red blood cell distribution width as a prognostic marker in patients with heart failure and diabetes mellitus
por: Xanthopoulos, Andrew, et al.
Publicado: (2017)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

The Relationship between Angiotensin–Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure
por: Zhang, Xiaoliang, et al.
Publicado: (2022)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
por: Dizaye, Kawa, et al.
Publicado: (2019)

Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study
por: Kourlaba, Georgia, et al.
Publicado: (2015)

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
por: Ryazanov, A.S., et al.
Publicado: (2023)

Identification and bioinformatic analysis of neprilysin and neprilysin-like metalloendopeptidases in Drosophila melanogaster
por: Meyer, Heiko, et al.
Publicado: (2021)

Relative contribution of risk factors/co‐morbidities to heart failure pathogenesis: interaction with ejection fraction
por: Giamouzis, Grigorios, et al.
Publicado: (2020)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
por: Sutanto, Henry, et al.
Publicado: (2021)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
por: Esser, Nathalie, et al.
Publicado: (2022)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Neprilysin Inhibitors and Bradykinin
por: Campbell, Duncan J.
Publicado: (2018)

Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention
por: Lianos, Ioannis, et al.
Publicado: (2022)

Red Blood Cell Distribution Width in Heart Failure: Pathophysiology, Prognostic Role, Controversies and Dilemmas
por: Xanthopoulos, Andrew, et al.
Publicado: (2022)

Defining Physiological Decompensation: An Expert Consensus and Retrospective Outcome Validation
por: Mitchell, Oscar J. L., et al.
Publicado: (2022)

Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost?
por: Xanthopoulos, Andrew, et al.
Publicado: (2022)

Heart failure with preserved ejection fraction: A distinct heart failure phenotype?
por: Triposkiadis, Filippos, et al.
Publicado: (2022)

Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena
por: AlAnazi, Faisal Holil, et al.
Publicado: (2023)

Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation
por: Tzeis, Stylianos, et al.
Publicado: (2020)

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696
por: Li, Bo, et al.
Publicado: (2017)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor
por: Kim, Moo Jun, et al.
Publicado: (2021)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
por: Li, Kangbo, et al.
Publicado: (2023)

Heart Failure 2012
por: Giamouzis, Gregory, et al.
Publicado: (2012)

Neprilysin, obesity and the metabolic syndrome
por: Standeven, Kristina F., et al.
Publicado: (2010)

Heart Failure
por: Giamouzis, Gregory, et al.
Publicado: (2011)

Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application
por: Bouchez, S., et al.
Publicado: (2018)

Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
por: Verbrugge, Frederik H., et al.
Publicado: (2020)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
por: Li, Wanjing, et al.
Publicado: (2022)

Glucose lowering does not necessarily reduce cardiovascular risk in type 2 diabetes
por: Bourazana, Angeliki, et al.
Publicado: (2022)

The Role of Neprilysin in Regulating the Hair Cycle
por: Morisaki, Naoko, et al.
Publicado: (2013)

Neprilysin inhibition in chronic kidney disease
por: Judge, Parminder, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9rk1ekr90r9hniadm8ilqs549v